Every 424B that OS Therapies Incorporated (OSTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow OSTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSTX filings page.
OS Therapies Inc. (OSTX) has filed a prospectus supplement registering up to 5,874,094 shares of common stock for resale by existing investors tied to its August 2026 senior secured note financing. The registered shares comprise 600,000 issued shares, 900,000 shares underlying pre-funded warrants, 1,500,000 shares underlying five-year warrants, and 2,874,094 shares issuable upon conversion of senior secured convertible notes.
The company will not receive proceeds from stockholder resales, but could receive about $4.28 million if all 1,500,000 warrants at $2.85 are exercised for cash, plus nominal proceeds from pre-funded warrants. The financing includes up to $10 million in senior secured convertible notes (first tranche principal $5.41 million) bearing 9.0% annual interest, maturing nine months after funding, and convertible at $2.05 per share, with a 4.99%–9.99% beneficial ownership cap. The notes are secured by a first‑priority lien on most assets and carry restrictive covenants, prepayment premiums, and a 125% acceleration feature on default, which, together with ATM issuances, could materially dilute existing holders and pressure the share price.
OS Therapies Inc (OSTX) is registering an at‑the‑market offering of up to $75,000,000 of common stock under a Sales Agreement with Jefferies LLC, which will receive a 3.0% commission on gross proceeds. Shares may be sold from time to time on the NYSE American, where the stock closed at $1.58 on August 20, 2026.
At an assumed price of $1.58, this would imply up to 47,468,354 new shares, compared with 46,470,790 shares outstanding as of August 20, 2026, for a potential total of 93,939,144 shares, excluding other convertible and exercisable securities. The company plans to use proceeds to fund clinical development and regulatory activities for OST‑HER2 and its OST‑tADC platform, advance R&D, pursue complementary acquisitions or investments, and for working capital and general corporate purposes.
The company discloses a significant net tangible book value deficit as of June 30, 2026, and its auditor’s report includes an explanatory paragraph regarding its ability to continue as a going concern. The dilution section illustrates that investors buying in this offering at $1.58 would experience immediate dilution of $0.98 per share based on pro forma, as adjusted figures.
OS Therapies Incorporated is registering and issuing 500,000 shares of common stock to Leonite Fund I, LP as part of the consideration under a July 31, 2026 settlement agreement resolving obligations related to a prior secured financing. The company will receive no cash proceeds; the shares are non‑cash consideration alongside a $1,900,000 cash payment funded via an August 2026 bridge note. Upon Leonite’s receipt of both the cash payment and these shares, a senior secured convertible note with up to $10,000,000 in principal, the related Leonite warrant and security interests will be extinguished, and previously assigned assets will revert to OS Therapies’ subsidiary free of Leonite’s lien. Shares outstanding are expected to be 46,125,825 after issuance, and the company estimates dilution to Leonite of $1.85 per share based on an assumed offering price of $1.60 and pro forma net tangible book deficit as of March 31, 2026.
OS Therapies Incorporated is offering 2,505,073 shares of common stock together with common warrants and, in lieu of some shares, pre-funded warrants to purchase up to 1,250,893 shares, plus common warrants to purchase up to 3,755,966 shares; placement agent warrants to purchase up to 187,798 shares are also included. The combined public offering price for each share and accompanying common warrant is $1.40; pre-funded warrants plus common warrant are priced at $1.399. The offering contemplates up to 5,006,859 shares of common stock underlying pre-funded warrants and common warrants in the aggregate. Net proceeds are estimated at approximately $4.7 million after fees and expenses, and delivery is expected on or about April 2, 2026. The securities are being placed on a best efforts basis by Ceros Financial Services, Inc., and the pre-funded warrants and common warrants will not be listed for trading.
OS Therapies registered 10,529,417 shares of common stock for resale by selling stockholders pursuant to a prospectus supplement dated March 31, 2026.
The registered shares consist of 2,622,774 shares issuable upon exercise of 2026 Warrants, 1,666,667 shares issuable upon exercise of Bridge Warrants and 6,239,976 shares issuable upon conversion of Bridge Notes. The company will receive no proceeds from resale by selling stockholders; it will receive proceeds only if outstanding warrants are exercised for cash.